Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study

C. Grana, M. Chinol, C. Robertson, C. Mazzetta, M. Bartolomei, C. De Cicco, M. Fiorenza, M. Gatti, P. Caliceti, G. Paganelli

Research output: Contribution to journalArticle

Abstract

In a previous study we applied a three-step avidin-biotin pretargeting approach to target 90Y-biotin to the tumour in patients with recurrent high grade glioma. The encouraging results obtained in this phase I-II study prompted us to apply the same approach in an adjuvant setting, to evaluate (i) time to relapse and (ii) overall survival. We enrolled 37 high grade glioma patients, 17 with grade III glioma and 20 with glioblastoma, in a controlled open non-randomized study. All patients received surgery and radiotherapy and were disease-free by neuroradiological examinations. Nineteen patients (treated) received adjuvant treatment with radioimmunotherapy. In the treated glioblastoma patients, median disease-free interval was 28 months (range=9-59); median survival was 33.5 months and one patient is still without evidence of disease. All 12 control glioblastoma patients died after a median survival from diagnosis of 8 months. In the treated grade III glioma patients median disease-free interval was 56 months (range= 15-60) and survival cannot be calculated as only two, within this group, died. Three-step radioimmunotherapy promises to have an important role as adjuvant treatment in high grade gliomas, particularly in glioblastoma where it impedes progression, prolonging time to relapse and overall survival. A further randomized trial is justified.

Original languageEnglish
Pages (from-to)207-212
Number of pages6
JournalBritish Journal of Cancer
Volume86
Issue number2
DOIs
Publication statusPublished - Jan 21 2002

Fingerprint

Radioimmunotherapy
Yttrium
Biotin
Glioma
Glioblastoma
Survival
Recurrence
Avidin
Radiotherapy

Keywords

  • Avidin-biotin
  • Glioma
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients : A pilot study. / Grana, C.; Chinol, M.; Robertson, C.; Mazzetta, C.; Bartolomei, M.; De Cicco, C.; Fiorenza, M.; Gatti, M.; Caliceti, P.; Paganelli, G.

In: British Journal of Cancer, Vol. 86, No. 2, 21.01.2002, p. 207-212.

Research output: Contribution to journalArticle

Grana, C. ; Chinol, M. ; Robertson, C. ; Mazzetta, C. ; Bartolomei, M. ; De Cicco, C. ; Fiorenza, M. ; Gatti, M. ; Caliceti, P. ; Paganelli, G. / Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients : A pilot study. In: British Journal of Cancer. 2002 ; Vol. 86, No. 2. pp. 207-212.
@article{2956d872dbcd4267927f2e694acbf7de,
title = "Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study",
abstract = "In a previous study we applied a three-step avidin-biotin pretargeting approach to target 90Y-biotin to the tumour in patients with recurrent high grade glioma. The encouraging results obtained in this phase I-II study prompted us to apply the same approach in an adjuvant setting, to evaluate (i) time to relapse and (ii) overall survival. We enrolled 37 high grade glioma patients, 17 with grade III glioma and 20 with glioblastoma, in a controlled open non-randomized study. All patients received surgery and radiotherapy and were disease-free by neuroradiological examinations. Nineteen patients (treated) received adjuvant treatment with radioimmunotherapy. In the treated glioblastoma patients, median disease-free interval was 28 months (range=9-59); median survival was 33.5 months and one patient is still without evidence of disease. All 12 control glioblastoma patients died after a median survival from diagnosis of 8 months. In the treated grade III glioma patients median disease-free interval was 56 months (range= 15-60) and survival cannot be calculated as only two, within this group, died. Three-step radioimmunotherapy promises to have an important role as adjuvant treatment in high grade gliomas, particularly in glioblastoma where it impedes progression, prolonging time to relapse and overall survival. A further randomized trial is justified.",
keywords = "Avidin-biotin, Glioma, Radioimmunotherapy",
author = "C. Grana and M. Chinol and C. Robertson and C. Mazzetta and M. Bartolomei and {De Cicco}, C. and M. Fiorenza and M. Gatti and P. Caliceti and G. Paganelli",
year = "2002",
month = "1",
day = "21",
doi = "10.1038/sj.bjc.6600047",
language = "English",
volume = "86",
pages = "207--212",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients

T2 - A pilot study

AU - Grana, C.

AU - Chinol, M.

AU - Robertson, C.

AU - Mazzetta, C.

AU - Bartolomei, M.

AU - De Cicco, C.

AU - Fiorenza, M.

AU - Gatti, M.

AU - Caliceti, P.

AU - Paganelli, G.

PY - 2002/1/21

Y1 - 2002/1/21

N2 - In a previous study we applied a three-step avidin-biotin pretargeting approach to target 90Y-biotin to the tumour in patients with recurrent high grade glioma. The encouraging results obtained in this phase I-II study prompted us to apply the same approach in an adjuvant setting, to evaluate (i) time to relapse and (ii) overall survival. We enrolled 37 high grade glioma patients, 17 with grade III glioma and 20 with glioblastoma, in a controlled open non-randomized study. All patients received surgery and radiotherapy and were disease-free by neuroradiological examinations. Nineteen patients (treated) received adjuvant treatment with radioimmunotherapy. In the treated glioblastoma patients, median disease-free interval was 28 months (range=9-59); median survival was 33.5 months and one patient is still without evidence of disease. All 12 control glioblastoma patients died after a median survival from diagnosis of 8 months. In the treated grade III glioma patients median disease-free interval was 56 months (range= 15-60) and survival cannot be calculated as only two, within this group, died. Three-step radioimmunotherapy promises to have an important role as adjuvant treatment in high grade gliomas, particularly in glioblastoma where it impedes progression, prolonging time to relapse and overall survival. A further randomized trial is justified.

AB - In a previous study we applied a three-step avidin-biotin pretargeting approach to target 90Y-biotin to the tumour in patients with recurrent high grade glioma. The encouraging results obtained in this phase I-II study prompted us to apply the same approach in an adjuvant setting, to evaluate (i) time to relapse and (ii) overall survival. We enrolled 37 high grade glioma patients, 17 with grade III glioma and 20 with glioblastoma, in a controlled open non-randomized study. All patients received surgery and radiotherapy and were disease-free by neuroradiological examinations. Nineteen patients (treated) received adjuvant treatment with radioimmunotherapy. In the treated glioblastoma patients, median disease-free interval was 28 months (range=9-59); median survival was 33.5 months and one patient is still without evidence of disease. All 12 control glioblastoma patients died after a median survival from diagnosis of 8 months. In the treated grade III glioma patients median disease-free interval was 56 months (range= 15-60) and survival cannot be calculated as only two, within this group, died. Three-step radioimmunotherapy promises to have an important role as adjuvant treatment in high grade gliomas, particularly in glioblastoma where it impedes progression, prolonging time to relapse and overall survival. A further randomized trial is justified.

KW - Avidin-biotin

KW - Glioma

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=18244367701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244367701&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6600047

DO - 10.1038/sj.bjc.6600047

M3 - Article

C2 - 11870507

AN - SCOPUS:18244367701

VL - 86

SP - 207

EP - 212

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -